Advertisement
Loading...

Formycon AG

FYB.DEXETRA
Healthcare
Biotechnology
19.06
-0.40(-2.06%)
German Market opens in 14h 20m

Formycon AG Fundamental Analysis

Formycon AG (FYB.DE) shows weak financial fundamentals with a PE ratio of -5.13, profit margin of -1.45%, and ROE of -16.02%. The company generates $0.0B in annual revenue with weak year-over-year growth of -10.32%.

Key Strengths

Cash Position20.73%
PEG Ratio-0.97
Current Ratio2.33

Areas of Concern

ROE-16.02%
Operating Margin-66.03%
We analyze FYB.DE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -104.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-104.8/100

We analyze FYB.DE's fundamental strength across five key dimensions:

Efficiency Score

Weak

FYB.DE struggles to generate sufficient returns from assets.

ROA > 10%
-8.75%

Valuation Score

Excellent

FYB.DE trades at attractive valuation levels.

PE < 25
-5.13
PEG Ratio < 2
-0.97

Growth Score

Weak

FYB.DE faces weak or negative growth trends.

Revenue Growth > 5%
-10.32%
EPS Growth > 10%
-2.53%

Financial Health Score

Excellent

FYB.DE maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
2.33

Profitability Score

Weak

FYB.DE struggles to sustain strong margins.

ROE > 15%
-1602.44%
Net Margin ≥ 15%
-1.45%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is FYB.DE Expensive or Cheap?

P/E Ratio

FYB.DE trades at -5.13 times earnings. This suggests potential undervaluation.

-5.13

PEG Ratio

When adjusting for growth, FYB.DE's PEG of -0.97 indicates potential undervaluation.

-0.97

Price to Book

The market values Formycon AG at 0.83 times its book value. This may indicate undervaluation.

0.83

EV/EBITDA

Enterprise value stands at -120.77 times EBITDA. This is generally considered low.

-120.77

How Well Does FYB.DE Make Money?

Net Profit Margin

For every $100 in sales, Formycon AG keeps $-1.45 as profit after all expenses.

-1.45%

Operating Margin

Core operations generate -66.03 in profit for every $100 in revenue, before interest and taxes.

-66.03%

ROE

Management delivers $-16.02 in profit for every $100 of shareholder equity.

-16.02%

ROA

Formycon AG generates $-8.75 in profit for every $100 in assets, demonstrating efficient asset deployment.

-8.75%

Following the Money - Real Cash Generation

Operating Cash Flow

Formycon AG generates strong operating cash flow of $11.34M, reflecting robust business health.

$11.34M

Free Cash Flow

Formycon AG generates strong free cash flow of $10.60M, providing ample flexibility for dividends, buybacks, or growth.

$10.60M

FCF Per Share

Each share generates $0.60 in free cash annually.

$0.60

FCF Yield

FYB.DE converts 3.19% of its market value into free cash.

3.19%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.13

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.97

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.83

vs 25 benchmark

P/S Ratio

Price to sales ratio

7.47

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.33

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.16

vs 25 benchmark

ROA

Return on assets percentage

-0.09

vs 25 benchmark

ROCE

Return on capital employed

-0.04

vs 25 benchmark

How FYB.DE Stacks Against Its Sector Peers

MetricFYB.DE ValueSector AveragePerformance
P/E Ratio-5.1329.94 Better (Cheaper)
ROE-16.02%738.00% Weak
Net Margin-145.46%-575975.00% (disorted) Weak
Debt/Equity0.020.44 Strong (Low Leverage)
Current Ratio2.334.49 Strong Liquidity
ROA-8.75%-15756.00% (disorted) Weak

FYB.DE outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Formycon AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

20.13%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-3032.89%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-781.44%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ